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Acceptability of medicines in children and caregivers affects safety and effectiveness of 26 
medicinal treatments. The pharmaceutical industry is required to demonstrate acceptability 27 
of new paediatric formulations in target age groups as an integrated part of the development 28 
of these products (P. Kozarewicz, 2014). Two questions arise when trying to tackle this task: 29 
“which dosage form to choose for each target age group?” and “how to formulate it once the 30 
dosage form is decided?”. Inevitably, both the regulator and the developer turn to scientific 31 
evidence for answers. Research has emerged in recent years to demonstrate age-32 
appropriateness and patient acceptability of different dosage forms; however, such 33 
information is still fragmented and far from satisfactory to define efficient formulation 34 
development strategies for a diverse patient subset (S. Ranmal and C. Tuleu, 2013). This 35 
paper highlights how formulation factors affect the acceptability of different oral medicines in 36 
children (Table 1), and it is based on a more extensive review article by Liu et al. (2014).  37 
Gaps in knowledge are highlighted in order to stimulate further research (F. Liu et al., 2014). 38 
In some areas, findings from studies conducted in adult populations may provide useful 39 
guidance for paediatric development and this is also discussed.  40 
 41 
Tablets and capsules are the most commonly developed dosage forms for adult populations. 42 
Efforts have been made in recent years to understand the relationship between acceptable 43 
tablet sizes and the age group of children. However, insufficient data has been reported so 44 
far to draw a conclusion or recommendation on the right tablet size for the right age group 45 
which is also driven by indication, motivation of the patient and carer, counselling from health 46 
care professionals, as well as other factors. A more systematic approach would benefit 47 
future research to close the gaps in knowledge in this area. Investigation into the effects of 48 
other features of tablets, such as shape, colour and surface coating, on acceptability in 49 
children is scarce. Whilst future research is needed in this area, knowledge gained in adult 50 
populations provides useful references. The use of capsules in children and the associated 51 
formulation considerations has yet to gain extensive attention in research. The ability of 52 
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children to take capsules in comparison to tablets and how formulation features such as size 53 
and density of capsules affect a child’s ability to swallow are the subjects of further research.  54 
 55 
Oral liquids are traditionally appraised as the first formulation of choice for children who 56 
cannot swallow tablets and capsules.  In recent years, shortcomings of liquids are 57 
recognised mainly including challenges in taste masking, stability issues and the use of 58 
numerous excipients, particularly preservatives. There is a consensus to move away from 59 
oral liquids to other flexible oral solid dosage forms such as multiparticulates and dispersible 60 
tablets (World Health Organisation, 2012). However, it should not be forgotten that oral 61 
liquids offer unique advantages including dose flexibility, ease of administration (usually no 62 
manipulation is required) and ease of ingestion. Moreover, their acceptance in children, and 63 
also with parents and healthcare professionals are well established as “the” paediatric 64 
medicine. The challenge is to apply innovative ideas to overcome the shortcomings of oral 65 
liquids and to optimise various characteristics of liquid formulations to improve acceptability, 66 
as listed in Table 1.  67 
 68 
As mentioned above, oral flexible solid dosage forms have come into fashion in the field of 69 
paediatric formulations as they offer easier oral ingestion for youngsters compared to tablets 70 
and capsules, and avoid many drawbacks related to liquid formulations. It is important to 71 
understand the unique advantages of each of these dosage forms and the associated 72 
challenges in formulation development. Multiparticulate dosage forms are versatile in use. 73 
They are suitable for use to children from birth and provide flexible methods of 74 
administration, such as reconstitution into a drink or as “sprinkles” onto food.  One risk 75 
associated with multiparticulates is chewing and this is particularly critical for modified 76 
release dosage forms. Particle size may be a “trigger” factor to initiate chewing response 77 
and the relationship between particle size and the risk of chewing needs investigation in 78 
future research. Dispersible, effervescent and chewable tablets share the same 79 
accountability of tooth erosion over the course of long-term use and the selection of 80 
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appropriate excipients is necessary to minimise such risks. Orally disintegrating tablets and 81 
films are relatively new innovations and have been proven to improve patient acceptance 82 
and compliance. The advance in these technologies could expand their application to a 83 
wider range of active ingredients and disease treatments.  84 
 85 
Scientific evidence that could guide paediatric formulation development is lacking in the 86 
literature.  Individual pharmaceutical companies gain experience and collect such data 87 
during product development and yet this is not available in the public domain. Regulatory 88 
bodies, academia and industry should work together to create an inventory of relevant 89 
parameters for oral formulation development to avoid duplication of efforts and provide 90 
consistent guidance.  91 
 92 
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Table 1 Formulation factors affecting acceptability of oral dosage forms 
 
Formulation platform  Summary of effects on acceptability 
Tablet  
 Size 
Mini-tablets (2-4 mm) were reported to be acceptable for children from 6 months of age (V. Klingmann et al., 
2013). Acceptability of tablets from 5 mm to 8 mm in size was evaluated in children from 1 to 11 years old in 
mixed age groups. Results from these studies were inconclusive as evidence for acceptability of tablets of 
different sizes in different age groups.  
 Shape 
No report was found as to how tablet shape affects acceptability in children. Studies in adult populations 
show that patients' preference of tablet shape is associated with its size. Generally, small tablets are 
preferred to be arched round and medium and large tablets are preferred to be oblong or oval.  
 Film coating 
Film coated and uncoated mini-tablets were both tested in children and two incidents of coughing or 
chocking were noted associating to coated tablets (V. Klingmann et al., 2013; S. A. Thomson et al., 2009). 
However, there is a lack of direct comparison of coated and uncoated tablets on swallowing performance in 
children.  
Capsule  
 
Comparison with 
tablet 
Direct comparison of acceptability of capsules with tablets in children has not been reported. Studies in 
adults show conflicting results; however, general caution when taking capsules was recommended due to the 
possibility of adhesion of the hydrated gelatin shell to oesophagus.  
 Size 
Acceptability of capsules in children in relation to size has not been reported. Studies in adults show that 
oesophageal transit of capsules was not affected by capsule size, in contrast to the significant influence of 
tablet size on its transit.  
 Density 
Effects of capsule density on swallowability in children were not reported. Studies in adults show that heavy 
capsules pass through the oesophagus significantly faster than light capsules.  
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Liquid  
 Taste 
Many reports and review articles have established that taste is fundamentally important in acceptability of 
liquid medicines in children. 
 Smell 
The smell of a liquid has been associated to its flavour and could contribute to the palatability of liquid 
medicines. Limited data has been reported to link medication odour to acceptability in children.  
 Viscosity 
No report was found on the effects of the viscosity of liquid medicines on acceptability and ease to swallow 
in children. Studies in adult populations and patients with dysphagia show that viscosity is associated to 
patient's perception of palatability of liquids. Thick liquids are deemed as unpleasant; however, these could 
improve swallowing safety in dysphagia patients.  
 Texture 
The texture of a liquid, especially grittiness and mouth feel of suspensions has been linked to particle size. 
The effects on acceptability in children have not been extensively studied.  
 Volume 
The ideal volume of liquid medicines should be swallowable in one unit. The average volume of liquid in one 
swallow is reported to be 4.5 ml in children from 15 months to 3.5 years of age (D. V. Jones and C. E. Work, 
1961). Very small volumes of oral liquids could be related to issues in dosing accuracy in children.  
Oral flexible solid dosage forms 
 Multiparticulates 
These are generally acceptable in children due to enhanced palatability and flexibility in administration such 
as mixing with semi-solid food. Grittiness and mouth feel are the main concerns in acceptability in children. 
The administration is considered to be time-consuming due to the need of reconstitution, which poses 
challenges to parents and carers.  
 
Dispersible and 
effervescent tablets 
Acceptability of dispersible tablets has been tested in children from 3 months to 8 years of age. These are 
generally more favourable compared to oral liquids such as syrup. However, the risk of tooth erosion needs 
to be considered for long-term use. The high quantity of sodium content in these formulations is associated 
to increased cardiovascular incidents in adults. The effect on long-term health in children has not been 
studied.  
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Orally disintegrating 
tablets 
These are generally well accepted in children due to the improved possibility to formulate a dosage form 
with improved taste and texture, ease of use and reduced concern about difficulties in swallowing.  
  Chewable tablets Chewable tablets are considered safe for children over the age of two years (T. M. Michele et al., 2002). The potential for tooth erosion over long-term use is still a consideration.  
 
 
